Navigation Links
Bayer and Onyx Announce Nexavar Data Presentations at 35th European Society for Medical Oncology Congress
Date:10/7/2010

Diabetes Care, and Pharmaceuticals divisions.  As a specialty pharmaceutical company, Bayer HealthCare Pharmaceuticals provides products for Diagnostic Imaging, General Medicine, Hematology, Neurology, Oncology and Women's Healthcare.  The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a selective proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801, an alpha-folate receptor targeted inhibitor of thymidylate synthase, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Forward-Looking Statements

This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management.  Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here.  These factors include those d
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)... , September 12, 2014 ... Market by Application [Beverages (Alcoholic, CSD, Sports & Energy ... Pet Food, Meat & Seafood)], by Material (Aluminum ... by MarketsandMarkets, defines and segments the Food & ... of each application in terms of volumes and ...
(Date:9/12/2014)... , Sept. 12, 2014 /PRNewswire-iReach/ -- 9 th ... 22-24, 2014 – Bethesda, MD ... http://www.fdanews.com/9thInspectionsSummitEarlyBird   Photo - http://photos.prnewswire.com/prnh/20140912/145652 ... for the next inspection than to get a glimpse ... during and after an inspection. Come to ...
(Date:9/12/2014)... 12, 2014 Research and Markets ... "Global Medical Technologies Market 2014-2018" report to ... a collective term for software solutions, medical devices, ... health. The Global Medical Technologies market covers active ... In vitro diagnostics technology, dental technology, electromechanical medical ...
Breaking Medicine Technology:Food & Beverage Metal Cans Market Worth $49.20 Billion by 2019 2Food & Beverage Metal Cans Market Worth $49.20 Billion by 2019 3Food & Beverage Metal Cans Market Worth $49.20 Billion by 2019 4FDAnews Announces: Early Bird Registration Discount Ends Sept.19 for 9th Annual Inspections Summit, Oct. 22-24, 2014 2FDAnews Announces: Early Bird Registration Discount Ends Sept.19 for 9th Annual Inspections Summit, Oct. 22-24, 2014 3Global Medical Technologies Market 2014-2018: Key Vendors are GE, Johnson & Johnson, Medtronic, Roche and Siemens 2Global Medical Technologies Market 2014-2018: Key Vendors are GE, Johnson & Johnson, Medtronic, Roche and Siemens 3
... and CAMPBELL, Calif. , May ... sophisticated risk characterization and personalized therapy guidelines for ... of advanced tests, offering an accompanying nutrition program, ... Director stated:  "With appropriate risk characterization and treatment, ...
... May 25 The U.S. Food and Drug Administration approved Lumizyme (alglucosidase ... a rare genetic disorder. , , ... http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) , , , ... an estimated 1 in every 40,000 to 300,000 births. Its primary symptom is ...
Cached Medicine Technology:Health Network Laboratories (HNL) Enters Into License Agreement With Hunter Laboratories to Provide HunterHeart Cardiovascular Disease Management Program. 2FDA Approves New Treatment for Late-Onset Pompe Disease 2FDA Approves New Treatment for Late-Onset Pompe Disease 3
(Date:9/15/2014)... September 15, 2014 PhySynergy, LLC, ... another new client partnership. PhySynergy will assume management ... this month. In addition to bringing strong leadership ... service capacity and anesthesia resources, by tapping into ... , “As we continue to invest in technologies ...
(Date:9/15/2014)... 15, 2014 Final Cut Pro X ... have announced a new Template the Qube Theme from Pixel ... a wide variety quality themes and the Qube theme adds ... Christian Austin, Pixel Film Studios CEO. “Qube theme has a ... Qube features intuitive controls that allow particle randomization, background color, ...
(Date:9/14/2014)... Petersburg, FL (PRWEB) September 15, 2014 Skin ... external factors like sun damage and not moisturizing properly. However, ... if skin has been cared for. , Two main reasons ... 2) Loss of hyaluronic acid in the skin , During ... and both of these are responsible for important moisture retention ...
(Date:9/14/2014)... Proper oral care requires about two ... found a way to teach children to brush their ... toothbrush encourages an effective brushing habit by ensuring that ... without overbrushing, eliminating guesswork and promoting independence and proper ... suitable for all children, and producible in design variations. ...
(Date:9/14/2014)... September 14, 2014 Top10BestSEOHosting.com always ... evaluating many web host suppliers carefully, the site ... and GoDaddy are the Best WordPress Hosting suppliers ... famous as a top web hosting provider, and ... is a web hosting provider known for its ...
Breaking Medicine News(10 mins):Health News:PhySynergy Wins Contract to Revive Anesthesia Services for Regional Hospital 2Health News:Announcing the Release of a New Template for Final Cut Pro X, The Qube Theme from Pixel Film Studios 2Health News:2 Reasons Skin Becomes Dryer with Age and What To Do About It, From Sublime Beauty® 2Health News:2 Reasons Skin Becomes Dryer with Age and What To Do About It, From Sublime Beauty® 3Health News:Top10BestSEOHosting.com: The Best Linux Web Hosting Suppliers Now Unveiled 2
... IRVINE, Calif., Oct. 9 DogChannel.com, the premier,online destination ... Medical,Conditions section, where visitors can find what may be ... The symptom list, located at http://www.DogChannel.com/medical ... Rugh, DVM, Ph.D. of,Rocheport, Missouri. The section contains the ...
... Analysis of 38 studies found painkillers showed protective effect ... drugs (NSAIDs) are associated with a reduced risk for ... findings aren,t an invitation for all women to start ... don,t want that to happen here, for people to ...
... 9 The National Academy of,Neuropsychology (NAN) will be ... Conference to be held October 22nd,through 25th at The ... New York.,The event will kick off with a full ... October 21, which includes an athlete panel,featuring former NHL ...
... CRME TSX: COM VANCOUVER, Oct. ... TSX: COM) today announced that it has been ... that an End of Review,meeting with the U.S. ... November 14th, 2008 regarding the New Drug Application ...
... Tournament to be held at Woodmont,Country Club on Oct. ... Sandler,and his wife, Froma, are still dealing with the ... disease of unknown origin that has no,cure. Lisa died ... The Sandlers have turned their grief into action as ...
... The following was,released by the U.S. ... ceremony for the Alzheimer,s,Awareness 42-cent social awareness ... Rockefeller Neurosciences Institute,s http://www.brni.org new,research ... D. Rockefeller IV, U.S. Postal Service ...
Cached Medicine News:Health News:DogChannel.com Launches Online Guide to Dog Medical Conditions 2Health News:NSAIDs Might Lower Breast Cancer Risk 2Health News:NSAIDs Might Lower Breast Cancer Risk 3Health News:National Academy of Neuropsychology to Focus on Effects of Sports Concussions at 2008 Conference 2Health News:Cardiome Provides Regulatory Update 2Health News:Cardiome Provides Regulatory Update 3Health News:Parents Host Golf Tournament to Fund Cure for Disease That Claimed Daughter's Life 2Health News:Parents Host Golf Tournament to Fund Cure for Disease That Claimed Daughter's Life 3Health News:Postal Service to Issue Alzheimer's Awareness Stamp 2
Free Estriol (E3) RIA Reproductive Hormones 024-IDC-2000...
Prolactin EIA Reproductive Markers 025-BC-1037...
... (17aOHP) is produced by both the ... has relatively little progestational activity, it ... it is the,immediate precursor to 11-desoxycortisol ... 21-hydroxylation of 17aOHP,measurement of 17aOHP is ...
FSH EIA Reproductive Markers 025-BC-1029 Follicle Stimulating Hormone...
Medicine Products: